

## DAFTAR PUSTAKA

1. Stewart SD, Allen S. Antibiotic use in critical illness. *J Vet Emerg Crit Care*. 2019;29(3):227–38.
2. Rajendran R, R. S, P. Y, M. V, V. D, M. A. Antibiotic efficacy patterns in the critically ill. *Int J Res Med Sci*. 2016;4(9):3702–8.
3. Maslove DM, Tang B, Shankar-Hari M, Lawler PR, Angus DC, Baillie JK, et al. Redefining critical illness. *Nat Med*. 2022;28(6):1141–8.
4. Davison JM, Wischmeyer PE. Probiotic and synbiotic therapy in the critically ill: state of the art. *Nutrition [Internet]*. 2019;59:29–36. Tersedia pada: <https://doi.org/10.1016/j.nut.2018.07.017>
5. McDonald D, Ackermann G, Khailova L, Baird C, Heyland D, Kozar R, et al. Extreme dysbiosis of the microbiome in critical illness. *mSphere*. 2016;1(4):1–6.
6. Ho KM, Kalgudi S, Corbett JM, Litton E. Gut microbiota in surgical and critically ill patients. *Anaesth Intensive Care [Internet]*. 2020;48(3):179–95. Tersedia pada: <https://doi.org/10.1177/0310057X20903732>
7. Otani S, Chihade DB, Coopersmith CM. Critical illness and the role of the microbiome. *Acute Med Surg*. 2019;6(2):91–4.
8. Savanur SS, Gururaj H. Study of antibiotic sensitivity and resistance pattern of bacterial isolates in intensive care unit setup of a tertiary care hospital. *Indian J Crit Care Med*. 2019;23(12):547–55.

9. Vitrat V, Hautefeuille S, Janssen C, Bougon D, Sirodot M, Pagani L. Optimizing antimicrobial therapy in critically ill patients. *Infect Drug Resist.* 2014;7:261–71.
10. Cohen J. Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients. *J Antimicrob Chemother.* 2013;68(3):490–1.
11. Tabah A, Lipman J, Barbier F, Buetti N, Timsit JF. Use of antimicrobials for bloodstream Infections in the intensive care unit, a clinically oriented review. *Antibiotics.* 2022;11(3).
12. Bass GA, Dzierba AL, Taylor B, Lane-Fall M, Kaplan LJ. Tertiary peritonitis: considerations for complex team-based care. *Eur J Trauma Emerg Surg* [Internet]. 2022;48(2):811–25. Tersedia pada: <https://doi.org/10.1007/s00068-021-01750-9>
13. Agudelo-Ochoa GM, Valdés-Duque BE, Giraldo-Giraldo NA, JaillierRamírez AM, Giraldo-Villa A, Acevedo-Castaño I, et al. Gut microbiota profiles in critically ill patients, potential biomarkers and risk variables for sepsis. *Gut Microbes* [Internet]. 2020;12(1). Tersedia pada: <https://doi.org/10.1080/19490976.2019.1707610>
14. Tosi M, Roat E, De Biasi S, Munari E, Venturelli S, Coloretti I, et al. Multidrug resistant bacteria in critically ill patients: a step further antibiotic therapy. *J Emerg Crit Care Med.* 2018;2:103–103.
15. Chaturvedi P, Lamba M, Sharma D, Mamoria VP. Bloodstream infections and antibiotic sensitivity pattern in intensive care unit. *Trop Doct.*

2021;51(1):44–8.

16. Radji M, Fauziah S, Aribinuko N. Antibiotic sensitivity pattern of bacterial pathogens in the intensive care unit of Fatmawati Hospital, Indonesia. *Asian Pac J Trop Biomed* [Internet]. 2011;1(1):39–42. Tersedia pada: [http://dx.doi.org/10.1016/S2221-1691\(11\)60065-8](http://dx.doi.org/10.1016/S2221-1691(11)60065-8)
17. Devian MK, Suranadi IW, Hartawan IGAGU, Aryabiantara IW. Bacterial patterns and sensitivity to antibiotics in patients treated with ventilators at the intensive care unit of Sanglah Hospital Denpasar, Bali, Indonesia. *Open Access Maced J Med Sci*. 2022;10:250–4.
18. Wunderink RG, Srinivasan A, Barie PS, Chastre J, Dela Cruz CS, Douglas IS, et al. Antibiotic stewardship in the intensive care unit: an official American thoracic society workshop report in collaboration with the aacn, chest, cdc, and scem. *Ann Am Thorac Soc* [Internet]. 2020;17(5):531–40.  
Tersedia pada: <https://doi.org/10.1513/AnnalsATS.202003-188ST>
19. Lipman J. Principles of antibiotic use. Chapter 72 in *Oh's Intensive Care Manual*. KPRA RSUD Dr.Soetomo. 2003.
20. Mer M, Lipman J. Antibiotic administration in the critically ill in need of intensive care! *South African Med J*. 2015;105(5):357–9.
21. Khilnani GC, Zirpe K, Hadda V, Mehta Y, Madan K, Kulkarni A, et al. Guidelines for antibiotic prescription in intensive care unit. *Indian J Crit Care Med*. 2019;23:1–63.

22. Udy AA, Roberts JA, Lipman J. Antibiotic pharmacokinetic/pharmacodynamic considerations in the critically ill. Vol. 4, Springer Nature. Singapura: Springer Nature; 2018. 75–89 hal.
23. McKenzie C. Antibiotic dosing in critical illness. *J Antimicrob Chemother.* 2011;66(2):25–31.
24. Gupta P. Physiological Changes in Hematological Profile among Healthy Pregnant Women Dr Priyanka Gupta. *IOSR J Dent Med Sci.* 2019;18(10):20–2.
25. Hassali MA, Alrawhi Y, Nouri A. Antibiotic sensitivity pattern in urinary tract infections at a secondary care Hospital in Oman. *Acta Sci Med Sci [Internet].* 2018;2(1):2–6. Tersedia pada:  
[https://www.researchgate.net/publication/32409429\\_Antibiotic\\_sensitivity\\_pattern\\_in\\_urinary\\_Tract\\_Infections\\_at\\_a\\_Secondary\\_Care\\_Hospital\\_in\\_Oman](https://www.researchgate.net/publication/32409429_Antibiotic_sensitivity_pattern_in_urinary_Tract_Infections_at_a_Secondary_Care_Hospital_in_Oman)
26. Coelho N, Cunha M. Padrão de Infecção e Antibioterapia em Unidade de Cuidados Intensivos. *Millenium.* 2020;2:317–38.
27. Lonsdale DO, Lipman J. Global personalization of antibiotic therapy in critically ill patients. *Expert Rev Precis Med Drug Dev [Internet].* 2021;6(2):87–93. Tersedia pada:  
<https://doi.org/10.1080/23808993.2021.1874823>
28. Vijayan AL, Ravindran S, Saikant R, Lakshmi S, Kartik R, Manoj G. Procalcitonin: A promising diagnostic marker for sepsis and antibiotic therapy. *J Intensive Care.* 2017;5(1):1–7.

29. Sager R, Kutz A, Mueller B, Schuetz P. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. *BMC Med* [Internet]. 2017;15(1):1–11. Tersedia pada: <http://dx.doi.org/10.1186/s12916-017-0795-7>
30. Mat Nor MB, Md Ralib A. Procalcitonin clearance for early prediction of survival in critically ill patients with severe sepsis. *Crit Care Res Pract*. 2014;2014.
31. Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. *Crit Care*. 2013;17(3).
32. Suberviola B, Castellanos-Ortega A, González-Castro A, García-Astudillo LA, Fernández-Miret B. Valor pronóstico del aclaramiento de procalcitonina, PCR y leucocitos en el shock séptico. *Med Intensiva*. 2012;36(3):177–84.
33. Kobayashi H, Amrein K, Lasky-Su JA, Christopher KB. Procalcitonin metabolomics in the critically ill reveal relationships between inflammation intensity and energy utilization pathways. *Sci Rep* [Internet]. 2021;11(1):1– 10. Tersedia pada: <https://doi.org/10.1038/s41598-021-02679-0>
34. Handayani N, Lardo S, Nugrohowati N. Difference of Procalcitonin Levels in Gram-Positive and Gram-Negative Bacterial Sepsis Patients of Indonesia Army Central Hospital Gatot Soebroto in 2016. *JUXTA J Ilm Mhs Kedokt Univ Airlangga*. 2022;13(1):38.

35. Yunus I, Fasih A, Wang Y. The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics. *PLoS One*. 2018;13(11):1–11.
36. Li B, Zhao X, Li S. Serum Procalcitonin Level and Mortality Risk in Critically ill Patients with Ventilator-Associated Pneumonia. *Cell Physiol Biochem*. 2015;37(5):1967–72.
37. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: A systematic review. *Clin Infect Dis*. 2011;53(4):379–87.
38. Zhu Y, Zhang R, Ye X, Liu H, Wei J. SAPS III is superior to SOFA for predicting 28-day mortality in sepsis patients based on Sepsis 3.0 criteria. *Int J Infect Dis* [Internet]. 2022;114:135–41. Tersedia pada: <https://doi.org/10.1016/j.ijid.2021.11.015>
39. Liu J, Gao Y, Wang X, Qian Z, Chen J, Huang Y, et al. Culture-positive spontaneous ascitic infection in patients with acute decompensated cirrhosis: Multidrug-resistant pathogens and antibiotic strategies. *Yonsei Med J*. 2020;61(2):145–53.
40. Paramythiotou E, Routsis C. Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients. *World J Crit Care Med*. 2016;5(2):111.
41. Tauran PM, Djaharuddin I, Bahrin U, Nurulita A, Katu S, Muchtar F, et al. Excess mortality attributable to antimicrobial-resistant bacterial bloodstream

- infection at a tertiary-care hospital in Indonesia. 2022;7:1–15. Tersedia pada: <http://dx.doi.org/10.1371/journal.pgph.0000830>
42. Jarrell AS, Kruer RM, Berescu LD, Pronovost PJ, Trivedi JB. Factors associated with in-hospital mortality among critically ill surgical patients with multidrug-resistant Gram-negative infections. *J Crit Care* [Internet]. 2018;43:321–6. Tersedia pada: <https://doi.org/10.1016/j.jcrc.2017.10.035>
  43. Lueangarun S, Leelarasamee A. Impact of inappropriate empiric antimicrobial therapy on mortality of septic patients with bacteremia: A retrospective study. *Interdiscip Perspect Infect Dis*. 2012;2012(December 2009).
  44. Fathi M, Markazi-Moghaddam N, Ramezankhani A. A systematic review on risk factors associated with sepsis in patients admitted to intensive care units. *Aust Crit Care* [Internet]. 2019;32(2):155–64. Tersedia pada: <https://doi.org/10.1016/j.aucc.2018.02.005>
  45. Angele MK, Pratschke S, Hubbard WJ, Chaudry IH. Gender differences in sepsis: Cardiovascular and immunological aspects. *Virulence*. 2014;5(1):12–9.
  46. Nasir N, Jamil B, Siddiqui S, Talat N, Khan FA, Hussain R. Mortality in sepsis and its relationship with gender. *Pakistan J Med Sci*. 2015;31(5):1201–6.
  47. Phua J, Ngerng WJ, See KC, Tay CK, Kiong T, Lim HF, et al. Characteristics and outcomes of culture-negative versus culture-positive severe sepsis. *Crit Care*. 2013;17(5).

48. Carmona CA, Marante A, Levent F, Marsicek S. Burkholderia cepacia Sepsis in a Previously Healthy Full-Term Infant. Case Rep Pediatr. 2020;2020:1–5.
49. Hua CN, Tokeshi J. Emergence of Burkholderia cepacia in Honolulu: a case of nursing home-acquired B. cepacia sepsis. Hawaii J Med Public Health. 2013;72(9):308–9.
50. Ballouz T, Aridi J, Afif C, Irani J, Lakis C, Nasreddine R, et al. Risk factors, clinical presentation, and outcome of Acinetobacter baumannii bacteremia. Front Cell Infect Microbiol. 2017;7(MAY):1–8.
51. Alexandraki I, Palacio C. Gram-negative versus Gram-positive bacteremia: What is more alarmin(g)? Crit Care. 2010;14(3).
52. Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis. Landes Biosci. 2014;5(1):213–8.
53. Brauncajs M, Bielec F, Macieja A, Pastuszek-Lewandoska D. Carbapenem-Resistant Gram-Negative Fermenting and Non-Fermenting Rods Isolated from Hospital Patients in Poland—What Are They Susceptible to? Biomedicines. 2022;10(12).
54. Goswami NN, Trivedi HR, Goswami APP, Patel TK, Tripathi CB. Antibiotic sensitivity profile of bacterial pathogens in postoperative wound infections at a tertiary care hospital in Gujarat, India. J Pharmacol Pharmacother. 2011;2(3):158–64.
55. Hestiyani RAN, Siswandari W, Indriani V, Peramiarti IDSAP, Anjarwati DU, Prihartini H. Antibiotic resistance of biofilm-producing bacteria from sepsis



- patients in Prof. Dr. Margono Soekarjo Hospital, Purwokerto, Central Java. *J Med Sci (Berkala Ilmu Kedokteran)*. 2022;54(2):161–70.
56. Colaço HG, Barros A, Neves-Costa A, Seixas E, Pedroso D, Velho T, et al. Tetracycline Antibiotics Induce Host-Dependent Disease Tolerance to Infection. *Immunity*. 2021;54(1):53-67.e7.
  57. Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. *Eur J Clin Microbiol Infect Dis*. 2022;41(7):1003–22.
  58. Madadi-Goli N, Moniri R, Bagheri-Josheghani S, Dasteh-Goli N. Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant *Acinetobacter baumannii*. *Iran J Microbiol*. 2017;9(1):19–25.
  59. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. *Am J Respir Crit Care Med*. 2006;174(1):84–93.
  60. Gregoriano C, Heilmann E, Molitor A, Schuetz P. Role of procalcitonin use in the management of sepsis. *J Thorac Dis*. 2020;2(Suppl 1):S5–15.
  61. Carr JA. Procalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unit. *J Intensive Care* [Internet]. 2015;3(1):1–8. Tersedia pada: <http://dx.doi.org/10.1186/s40560-015-0100-9>

62. Sartori LF, Zhu Y, Grijalva CG, Ampofo K, Gesteland P, Johnson J, et al. Pneumonia severity in children: Utility of procalcitonin in risk stratification. *Hosp Pediatr*. 2021;11(3):215–22.
63. Evans J, Hannoodee M, Wittler M. Amoxicillin Clavulanate. *StatPearls Publ*. 2022;
64. Yang L, Lin Y, Wang J, Song J, Wei B, Zhang X, et al. Comparison of clinical characteristics and outcomes between positive and negative blood culture septic patients: A retrospective cohort study. *Infect Drug Resist*. 2021;14(October):4191–205.
65. Minasyan H. Sepsis: Mechanisms of bacterial injury to the patient. *Scand J Trauma Resusc Emerg Med*. 2019;27(1):1–22.
66. Ohnuma T, Chihara S, Costin B, Treggiari MM, Bartz RR, Raghunathan K, et al. Association of Appropriate Empirical Antimicrobial Therapy With In-Hospital Mortality in Patients With Bloodstream Infections in the US. *JAMA Netw Open*. 2023;6(1):E2249353.





KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN  
 RSPTN UNIVERSITAS HASANUDDIN  
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.IO MAKASSAR 90245.  
 Contact Person: dr. Agussalim spGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

**REKOMENDASI PERSETUIUAN ETIK**

Nomor : 789/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 6 Desember 2022 Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah menda atkan Persetu•uan Etik •

No Protokol	UH22110709	No Sponsor Protokol	
Peneliti Utama	dr. Fradita Yudiastri Yunus Guzasiah	S onsor	
Judul Peneliti	HUBUNGAN TERAPI ANTIBIOTIK SESIJAI KULTUR BAKTERI TERHADAO KLIRENS PROKALSITONIN DAN MORTALITAS PADA PASIEN SEPSIS DI INSTALASI PERAWATAN INTENSIF RSUP DR. WAHIDIN SUDIROHUSODO		
No Versi Protokol	1	Tanggal Versi	21 Nopember 2022
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="radio"/> Exempted <input checked="" type="radio"/> Expedited <input type="checkbox"/>	Masa Berlaku 6 Desember 2022 sampai	Frekuensi review lanjutan

	Fullboard Tanggal	6 Desember 2023	
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,sp.GK (K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
  - Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
  - Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
  - Menyerahkan laporan akhir setelah Penelitian berakhir
  - Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation) ●
- Mematuhi semua peraturan yang ditentukan